Preferences help
enabled [disable] Abstract
Number of results
2014 | 61 | 4 | 833-836
Article title

Cytotoxicity of anticancer aziridinyl-substituted benzoquinones in primary mice splenocytes

Title variants
Languages of publication
The anticancer activity of aziridinyl-quinones is mainly attributed to their NAD(P)H:quinone oxidoreductase 1 (NQO1)-catalyzed two-electron reduction into DNA-alkylating products. However, little is known about their cytotoxicity in primary cells, which may be important in understanding their side effects. We found that the cytotoxicity of aziridinyl-unsubstituted quinones (n = 12) in mice splenocytes with a low amount of NQO1, 4 nmol × mg-1 × min-1, was caused mainly by the oxidative stress. Aziridinyl-benzoquinones (n = 6) including a novel anticancer agent RH1 were more cytotoxic than aziridinyl-unsubstituted ones with the similar redox properties, and their cytotoxicity was not decreased by an inhibitor of NQO1, dicumarol. The possible reasons for their enhanced cytotoxicity are discussed.
Physical description
  • Institute of Biochemistry of Vilnius University, Vilnius, Lithuania
  • Institute of Biochemistry of Vilnius University, Vilnius, Lithuania
  • Institute of Biochemistry of Vilnius University, Vilnius, Lithuania
  • Alcain FJ, Villalba JM (2007) NQO1-directed antitumour quinones. Expert Opin Ther Pat 17: 649-665.
  • Anusevičius Ž, Nivinskas H, Šarlauskas J, Sari MA, Boucher JL, Čėnas N (2013) Single-electron reduction of quinone and nitroaromatic xenobiotics by recombinant rat neuronal nitric oxide synthase. Acta Biochim Pol 60: 217-222.
  • Begleiter A (2000) Clinical applications of quinone-containing alkylating agents. Frontiers Biosci 5: e153-e171.
  • Cameron DW, Gilles RGF (1968) Photochemical formation of benzoxalizone derivatives from aminated quinones. J Chem Soc C 1461-1464.
  • Čėnas N, Anusevičius Ž, Nivinskas H, Misevičienė L, Šarlauskas J (2004) Structure-activity relationships in two-electron reduction of quinones. Methods Enzymol 382: 258-277.
  • Chou F, Khan AH, Driscoll JS (1976) Potential central nervous system antitumour agents. Aziridinylbenzoquinones. J Med Chem 19: 1302-1308.
  • Danson SJ, Johnson P, Ward TH, Dawson M, Denneny O, Dickinson G, Aarons L, Watson A, Jowle D, Cummings J, Robson L, Halbert G, Dive C, Ranson M (2011) Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Ann Oncol 22: 1653-1660.
  • Di Francesco A, Ward TH, Butler J (2004) Diaziridinylbenzoquinones. Methods Enzymol 382: 174-193.
  • Hacker MP, Hong CB, McKee MJ, Unwin SE, Urbanek SA (1982) Toxicity of aziridinylbenzoquinone administrated intra venously to beagle dogs. Cancer Treat Rep 66: 1845-1852.
  • Hargreaves RHJ, Hartley JA, Butler J (2000) Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. Frontiers Biosci 5: e172-e180.
  • Huang CH, Kuo HS, Liu JW, Lin YL (2009) Synthesis and antitumor evaluation of novel bis-triaziquone derivatives. Molecules 14: 2306-2316.
  • Hussein D, Holt SV, Brookes KE, Klymenko T, Adamski JK, Hogg A, Estlin EJ, Ward T, Dive C (2009) Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours. Br J Cancer 101: 55-63.
  • Kligerman AD, Erexson GL, Bryant MF (1988) Sister chromatid exchange induction by diaziquone in human and mouse lymphocytes following both in vivo and in vitro exposures. Cancer Res 48: 27-31.
  • Lee CS, Hartley JA, Berardini MD, Butler J, Siegel D, Ross D, Gibson NW (1992) Alteration in DNA cross-linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT-diaphorase. Biochemistry 31: 3019-3025.
  • Li B, Gutierrez PL, Amstad P, Blough NV (1999) Hydroxyl radical production by mouse epidermal cell lines in the presence of quinone anti-cancer compounds. Chem Res Toxicol 12: 1042-1049.
  • Lind C, Cadenas E, Hochstein P, Ernster L (1990) DT-diaphorase: purification, properties, and function. Methods Enzymol 186: 287-301.
  • Nemeikaitė-Čėnienė A, Šarlauskas J, Anusevičius Ž, Nivinskas H, Čėnas N (2003) Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H:quinone oxidoreductase (NQO1) and oxidative stress. Arch Biochem Biophys 416: 110-118.
  • Oberley LW, Buettner GR (1979) Role of superoxide dismutase in cancer: a review. Cancer Res 39: 1141-1149.
  • O'Brien PJ (1991) Molecular mechanisms of quinone cytotoxicity. Chem-Biol Interact 80: 1-41.
  • Öllinger K, Brunmark A (1991) Effect of hydroxy substituent position on 1,4-naphthoquinone toxicity to rat hepatocytes. J Biol Chem 266: 21496-21503.
  • Parkinson EI, Bair JS, Cismesia M, Hergenrother PJ (2013) Efficient NQO1 substrates are potent and selective anticancer agents. ACS Chem Biol 8: 2173-2183.
  • Petersen S, Gauss W, Urbschat E (1955) Synthese einfacher chinon-derivation mit fungiziden, bakteriostatischen oder cytostatischen eigenschaften. Angew Chem 67: 1461-1464.
  • Schallreuter KU, Wood JK, Berger J (1991) Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermacol 97: 1081-1085.
  • Stack AS, Altman-Hamamdzic S, Morris PJ, London SD, London L (1999) Polychlorinated biphenyl mixtures (Aroclors) inhibit LPS-induced murine splenocyte proliferation in vitro. Toxicology 139: 137-154.
  • Tudor G, Alley M, Nelson CM, Huang R, Covell D, Gutierrez P, Sausville EA (2005) Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction. Anti-Cancer Drugs 16: 381-391.
  • Ward TH, Danson S, McGown AT, Ranson M, Coe NA, Jayson GC, Hargreaves RHJ, Butler J (2005) Preclinical evaluation of the pharmacodynamic properties of 2,3-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone. Clin Cancer Res 11: 2695-2701.
  • Wardman P (1989) Reduction potentials of one-electron couples involving their radicals in aqueous solutions. J Phys Chem Ref Data 18: 1637-1755.
  • Wardman P, Dennis MF, Everet SA, Patel KB, Stratford MR, Tracy M (1995) Radicals from one-electron reduction of nitro compounds, aromatic N-oxides and quinones: the kinetic basisfor hypoxia-selective bioreductive drugs. Biochem Soc Symp 61: 171-194.
  • Winski SL, Hargreaves RHJ, Butler J, Ross D (1998) A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumour quinones: Identification of a new aziridinylbenzoquinone RH1, an NQO1-directed antitumour agent. Clin Cancer Res 4: 3083-3088.
  • Winski SL, Swann E, Hargreaves RHJ, Dehn DL, Butler J, Moody CJ, Ross D (2001) Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 61: 1509-1516.
  • Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D (2008) Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumour agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). Mol Pharmacol 74: 1657-1665.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.